{
    "nctId": "NCT00855114",
    "briefTitle": "Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery",
    "officialTitle": "A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Decrease of total choline in at least 30% of patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of invasive breast cancer\n\n  * Resectable disease\n* Measurable disease, defined as a primary breast mass \\> 2.0 cm by breast imaging or clinical exam\n* Planning to undergo surgical resection after neoadjuvant therapy\n* Menopausal status not specified\n* Eastern Clinical Oncology Group (ECOG) performance status 0-1\n* Absolute neutrophil count (ANC) \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \\> 9.0 g/dL\n* Aspartate aminotransferase/alanine aminotransferase (AST/ALT) \u2264 2.5 times upper limit of normal (ULN)\n* Creatinine \u2264 1.5 times ULN\n* Total bilirubin \u2264 1.5 times ULN\n* Not pregnant\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nExclusion Criteria:\n\n* Intracranial disease\n* Hormone receptor status not specified\n* Obese (\\> 250 pounds)\n* Immunosuppression from any cause (e.g., known HIV infection)\n* History of severe asthma and/or allergies\n* History of severe claustrophobia\n* Ferromagnetic implants, history of shotgun wound and/or shrapnel, cardiac pacemakers, or other similar situations that would be contrary to strong magnetic force\n* Bleeding diathesis\n* Unstable systemic disease, including but not limited to, any of the following:\n\n  * Uncontrolled diabetes\n  * Severe infection\n  * Severe malnutrition\n  * Uncontrolled hypertension\n  * Unstable angina\n  * Ventricular arrhythmias\n  * Active ischemic heart disease\n  * Congestive heart failure\n  * Myocardial infarction within the past 6 months\n  * Chronic liver disease\n  * Renal disease\n  * Active upper gastrointestinal tract ulceration\n* Less than 4 weeks since prior investigational drug\n* Prior therapy with sirolimus or its analogues\n* Concurrent immunosuppressive therapy (e.g., steroids, cytotoxic agents, or concurrent radiotherapy)\n* Concurrent anticoagulation (i.e., coumadin)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}